NASH - Nonalcoholic Steatohepatitis Clinical Trial
Official title:
Non Alcoholic Steatohepatitis in Relation to Visceral and Subcutaneous Fat
Evaluate the relationship between the severity of fatty liver in NAFLD assessed by ultrasonography and CT and the visceral fat area measured by CT
Non alcoholic fatty liver disease is one of the most common causes of chronic liver disease
world wide . Severe forms of NAFLD such as nonalcoholic steatohepatitis can progress to
end-stage liver disease such as cirrhosis or hepatocellular carcinoma. Therefore,
investigating risk factors associated with hepatic steatosis is required to perform effective
screening .
Hepatic steatosis develops for a variety reasons but obesity is the most common associated
condition.
Obesity is considered a gateway disease and NAFLD is considered to be one of the phenotypes
of metabolic syndrome, which is characterized by obesity with visceral fat accumulation,
diabetes, hypertension and dyslipidemia.
Individuals with severe obesity have a disproportionately high risk of comorbidities
including nonalcoholic fatty liver disease (NAFLD), cardiovascular disease and diabetes.
The distribution of fat appears more important than the total fat mass in obesity .A
predominantly upper body fat distribution increases the risks for the metabolic complications
of obesity including hepatic steatosis especially when it is associated with increased intra
abdominal fat .
Most "metabolically obese" normal weight subjects have some increase in adipose tissue mass
and insulin resistance probably due to an increase in visceral fat. Thus, subjects with a
relatively low BMI can have gross increases in abdominal visceral fat, and others with a high
BMI may have very little intra abdominal/visceral fat .
Several studies suggested visceral adiposity to be a clinical predictor of hepatic steatosis
.
In addition, the severity of fatty liver has been linked to the VAT area as evaluated by CT.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
| Active, not recruiting |
NCT05479721 -
LITMUS Imaging Study
|
||
| Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
| Recruiting |
NCT04976283 -
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
|
Phase 4 | |
| Completed |
NCT02784444 -
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
|
Phase 2 | |
| Not yet recruiting |
NCT05499949 -
The Franciscus Obesity NASH Study
|
||
| Completed |
NCT04321343 -
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Recruiting |
NCT04371042 -
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
|
||
| Not yet recruiting |
NCT03648554 -
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
|
Phase 4 | |
| Completed |
NCT04972396 -
ALT-801 DDI Study in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT03748628 -
Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
|
Phase 1 | |
| Enrolling by invitation |
NCT05195944 -
Semaglutide vs Sitagliptin
|
Phase 4 | |
| Completed |
NCT04643795 -
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
|
Phase 1 | |
| Terminated |
NCT03669133 -
Vitamin E for NASH Treatment in HIV Infected Individuals
|
Phase 2 | |
| Completed |
NCT04066400 -
Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis
|
N/A | |
| Completed |
NCT03536650 -
Effect of DMR in the Treatment of NASH
|
N/A | |
| Completed |
NCT03783897 -
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
|
Phase 1 | |
| Completed |
NCT04618744 -
A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Active, not recruiting |
NCT05338034 -
Phase 2a Study of HPG1860 in Subjects With NASH
|
Phase 2 | |
| Active, not recruiting |
NCT04653103 -
NASH in Subjects With Different Classes of Obesity
|